SCHEMBL6883085

SCHEMBL6883085

CCOC(=O)c1cnc2c(c1)/C(=C/Nc1ccc(-n3[nH]c(=O)cc3C)cc1)C(=O)N2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.41
MAPT P10636 9/20 0.37
SMN1; SMN2 Q16637 7/20 0.37
KMT2A Q03164 6/20 0.37
MEN1 O00255 5/20 0.37
HTT P42858 2/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
RAB9A P51151 6/20 0.36
NPC1 O15118 5/20 0.36
MDM2 Q00987 1/20 0.35
MAPK1 P28482 2/20 0.34
PKM P14618 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HPGD P15428 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6883094 1.00 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL7667897 0.89 KMT2A (0.33) ALDH1A1MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL5873743 0.84 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL5873740 0.84 ALDH1A1 (0.46) ALDH1A1MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL6880716 0.82 NTRK1 (0.39) ALDH1A1MAPTKMT2AMEN1RAB9A
SCHEMBL6880710 0.82 NTRK1 (0.39) ALDH1A1MAPTKMT2AMEN1RAB9A
SCHEMBL5428534 0.81 KMT2A (0.47) ALDH1A1MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL5172094 0.81 KMT2A (0.47) ALDH1A1MAPTSMN1; SMN2KMT2AMEN1
SCHEMBL5873919 0.80 JAK3 (0.38) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL5873921 0.80 JAK3 (0.38) ALDH1A1MAPTKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US claimed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US claimed
US-6818632-B2 3-(anilinomethylene)oxindoles SMITHKLINE BEECHAM CORPORATION 2004-11-16 US disclosed
US-6498176-B1 INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS SMITHKLINEBEECHAM CORPORATION 2002-12-24 US disclosed
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia GLENNON KIMBERLEY CAROLINE (US) 2002-07-25 US disclosed
US-6350747-B1 PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS GLAXO WELLCOME INC. 2002-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099071-A1 Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia PRKDC, PRKX, BMX ALDH1A1 4171/4885MAPT 2317/4885SMN1; SMN2 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.